Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAK7
REST API REST API
Homo sapiens
PAK7 is differentially expressed in 171 experiments: 118 organism parts: brain, cerebellum, ... (116 more);, 123 disease states: normal, neuroblastoma, ... (121 more);, 51 cell types 149 cell lines 18 compound treatments and 66 other conditions.
Synonyms KIAA1264, PAK5
Orthologs PAK7 (Gallus gallus)   Pak7 (Mus musculus)   PAK7 (2 of 2) (Danio rerio)   Pak7 (Rattus norvegicus)   STE20 (Saccharomyces cerevisiae)   PAK7 (Bos taurus)   pak7 (Danio rerio)   mbt (Drosophila melanogaster)   pak7 (Xenopus laevis)   PAK7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cell migration, cytoskeleton organization, protein binding, apoptosis, cell proliferation, protein tyrosine kinase activity, anti-apoptosis, cell growth, ATP binding, nucleotide binding, protein serine/threonine kinase activity, signal transduction, protein kinase activity, mitochondrion, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, PAK_box_Rho-bd, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q9UJQ0, B3KTJ2, Q9P286
Search EB-eye ENSG00000101349
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-MTAB-24, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-MEXP-1006, E-GEOD-19639, ... (20 experiments)

Factor Value U/D Experiments
MDA-MB-231
2
E-TABM-420, E-MTAB-62
HS578T
1
E-MTAB-62
NCIH522
1
E-MTAB-37
Calu1
1
E-MTAB-37
Hep3B
1
E-MTAB-37
cultured 24 hours
1
E-MTAB-62
143 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, ... (30 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-MEXP-1327
B cell
3
1
E-GEOD-13987
CD19+ B cells (neg. sel.)
2
1
E-AFMX-5
erythropoietic
1
E-GEOD-9894
plasmablast
1
E-MEXP-2360
45 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-2466, E-MEXP-2069, ... (41 experiments)

Factor Value U/D Experiments
colon carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MEXP-567
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
neuroblastoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-1825
cockayne syndrome
1
E-MTAB-62
sporadic basal-like breast cancer
1
E-GEOD-3744
117 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5824, E-GEOD-5099, E-MEXP-941, E-GEOD-5418, ... (13 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
PGE2
1
1
E-MEXP-1230
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
bacterial endotoxin
1
1
E-GEOD-3284
phorbol 12-myristate 13-acetate
1
E-GEOD-995
valproic acid
1
E-GEOD-1615
12 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
29
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-TABM-145, E-MTAB-62

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-MEXP-2280, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genotype
studied in E-TABM-763, E-GEOD-22056, E-GEOD-2466, E-GEOD-21750

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-GEOD-20540, E-GEOD-10315

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, E-GEOD-6919, ... (23 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.6 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM